Wayland Group Corp Stock Canadian Securities Exchange
Equities
CA5667241007
Pharmaceuticals
Sales 2016 | 4.06 5.58 | Sales 2017 | 3.22 4.43 | Capitalization | 203M 279M |
---|---|---|---|---|---|
Net income 2016 | -8M -11M | Net income 2017 | -67M -92.09M | EV / Sales 2016 * | - |
Net Debt 2016 | 9.13 12.55 | Net cash position 2017 | 0.42 0.57 | EV / Sales 2017 | 63,046,727 x |
P/E ratio 2016 * |
-
| P/E ratio 2017 |
-2.13
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
1st Jan change | Capi. | |
---|---|---|
+40.86% | 6.18B | |
-16.30% | 4.46B | |
-9.93% | 3.15B | |
-1.58% | 3.01B | |
-1.70% | 2.55B | |
+37.23% | 1.83B | |
-12.78% | 1.59B | |
+1.02% | 1.66B | |
-12.97% | 1.53B |